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Abstract
Purpose: To investigate risk factors associated with progressive visual field (VF) loss in primary angle closure
glaucoma (PACG).
Methods: We retrospectively reviewed medical record of PACG patients who had ≥5 reliable VF examinations
(central 24-2 threshold test, Humphrey Field Analyzer) and ≥2 years of follow-up. Each VF was scored using
Collaborative Initial Glaucoma Treatment Study system. Progression was defined if 3 consecutive follow-up VF tests
had an increased score of ≥3 above the mean of the first 2 VF scores. Factors associated with VF progression were
evaluated by Cox proportional hazards models.
Results: A total of 89 eyes from 89 patients (mean age, 69.8 ± 7.9 years), who received a mean of 6.9 ± 2.3 VF tests
(mean deviation at initial, -8.1 ± 4.4 dB) with a mean follow-up of 63.9 ± 23.9 months were included. VF progression
was detected in 9 eyes (10%). The axial length (AL), anterior chamber depth, and intraocular pressure (IOP) in
patients with and without progression were 22.5 ± 0.6 and 23.1 ± 0.9 mm, 2.5 ± 0.3 and 2.5 ± 0.3 mm, 14.8 ± 2.4 and
14.3 ± 2.3 mm Hg, respectively. AL was the only factor associated with progression in both Cox proportional hazards
univariate (p = 0.031) and multivariate models (p = 0.023).
Conclusion: When taking into account age, IOP, follow-up period, and number of VF tests, a shorter AL is the only
factor associated with VF progression in this cohort of Chinese patients with PACG. Further studies are warranted to
verify the role of AL in progressive VF loss in PACG.
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Introduction
Glaucoma is the second leading cause of blindness
worldwide [1,2]. The proportion of blindness caused by angle
closure glaucoma (ACG) is greater than that caused by open
angle glaucoma (OAG) [1,3]. Quigley et al estimated that the
number of people with bilateral blindness from ACG will be 5.3
million by 2020 [3]. More than 80% of ACG patients resides in
Asia, and around 50% lives in China [3].
The well-known risks factors for visual field (VF) progression
in glaucoma were learned mostly from studies on OAG,
including Collaborative Initial Glaucoma Treatment Study
(CIGTS) [4], Collaborative Normal Tension Glaucoma Study
[5], Advanced Glaucoma Intervention Study (AGIS) [6], and
Early Manifest Glaucoma Trial (EMGT) [7]. The identified risk
factors include: older age [8], higher baseline intraocular
pressure (IOP) [8], higher IOP during the follow-up period
[5,6,9] thinner central corneal thickness (CCT) [8], self-reported
diabetes mellitus [4,10], more severe VF mean deviation (MD)
at baseline [9], lower blood pressure [8], presence of migraine
[11], presence of disc hemorrhage [8,9,11], and wider IOP
fluctuation [12]. Only few studies have assessed risk factors
associated with disease progression in primary ACG (PACG).
Hong et al reported chronic PACG patients with thinner CCT
were at risk of VF progression by comparing the final and
earliest VF MD [13]. Since MD is subject to many factors such
as test variability and lens opacity, comparing MD between two
time points may not reflect true glaucoma progression. Another
retrospective study conducted by the same group found that
long-term IOP fluctuation was associated with progressive VF
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deterioration in PACG [14]. According to Quek et al, neither
mean IOP nor IOP range was a risk factor of VF progression in
PACG without prior acute angle closure (AAC) [15]. Therefore,
risk factors for VF progression in PACG remain elusive.
To determine risk factors of disease progression is crucial in
the management of PACG and prevention of blindness. Thus,
the purpose of this study was to investigate the rate of and risk
factors associated with VF progression in Chinese patients with
PACG.
Methods
This retrospective study reviewed medical record of all
patients who met the International Classification of Disease,
9th revision, Clinical Modification (ICD-9-CM): 365.23, chronic
angle closure glaucoma in 2008 at Taipei Veterans General
Hospital, a tertiary referral hospital. Data of each patient were
collected since the date when the first of the two reliable
baseline VF tests was accomplished. The Institutional Review
Board (IRB) for Human Research at the Taipei Veterans
General Hospital approved our review of patient records in this
study. Informed written consent was waived by the approving
IRB.
Patients were included if they had received regular follow-up
(every 1–4 months) at glaucoma service for at least 2 years
with 5 or more reliable VF tests (≤33% fixation losses, ≤33%
false-negative results, and ≤33% false-positive results). All
subjects met the following inclusion criteria: eyes with an
occludable angle; glaucomatous optic neuropathy with
corresponding VF defects; and a best-corrected visual acuity
(BCVA) of 20/100 or better throughout the study period. An
occludable angle was defined if the posterior trabecular
meshwork was invisible on gonioscopy for at least 270° of the
angle circumference in the primary position without indentation
[16]. Glaucomatous optic disc was defined as a vertical cup to
disc ratio (VCDR) of the optic nerve head ≥0.7, a VCDR
difference of ≥0.2 between eyes, or focal thinning, notching, or
excavation of the neuroretinal rim. VF tests were conducted
with a Humphrey Field Analyzer set for the central 24-2
threshold test with size III white stimulus (Carl Zeiss Meditec,
Inc, Dublin, California, USA). Abnormal VF tests were defined
as outside normal limits of glaucoma hemifield test or pattern
standard deviation (PSD) outside the 95% normal limits.
Patients with the following conditions were excluded:
secondary angle closure glaucoma attributed to medicine or
other ocular abnormalities; history of ocular surgery other than
cataract or glaucoma surgery; corneal pathologic features; and
other retinal or neurologic diseases that could possibly be
associated with VF progression. This study used the CIGTS
scoring system to identify VF progression. Patients with a
mean CIGTS score of the first 2 VFs that exceeded 17.0 were
excluded. If both eyes of one patient were eligible, the eye with
the worse VF MD was included in the study.
Data recorded included patient demographics, past history,
personal history, family history, systemic diseases, and
ophthalmic findings. Axial length (AL), anterior chamber depth
(ACD), and lens thickness of the phakic eye were measured by
a contact ultrasound biometry (A-scan, Sonomed Inc., USA). If
an A-scan had not been performed, AL and ACD measured by
IOL Master (Version 5.02; Carl Zeiss Meditec Ltd, Jena,
Germany) were recorded. For patients who were pseudophakic
at enrollment into this study, only AL was recorded. CCT was
measured by ultrasonic pachymetry. All IOP measurements
before VF progression were recorded. To avoid short-term
fluctuations in IOP that resulted from operation or intervention,
we disregarded the IOP within one month after operation or
needling of the bleb and within one week after laser treatment.
The mean IOP represented the mean of all recorded IOP
values. Highest IOP (peak IOP) was also recorded. Standard
deviation of the IOP was used as a surrogate for IOP
fluctuation. The IOP range represented the value of the highest
IOP minus the lowest IOP during the study period.
Progression of VF loss
The VF score was generated from the total deviation
probability plot values on the Humphrey 24-2 printout based on
the methods developed in CIGTS [17]. In brief, each of the 52
points was deemed as a point of defect if its probability value
was 0.05 or less. A weight was assigned depending on the
minimum depth of the defect at the given point and its 2 most
defective neighboring points in the same hemifield, which
ranged from 1 to 4. The weights for all 52 points were summed,
then divided by 10.4 to obtain a value between 0 (normal) and
20 (perimetrically blind) [17].
Evidence of progression was declared if the overall CIGTS
VF score increased by 3 or more above the mean of the first 2
VF scores on 3 consecutive tests at different visits.
Statistical analysis
Independent samples t-test was used to compare continuous
variables between patients with and without progression and
the Pearson Chi-Square was used for categorical variables
comparison. Hazard ratios (HRs) for the association between
risk factors and progression of VF defects (yes or no) were
obtained using Cox proportional hazards models based on the
follow-up time until progression. Variables with a p < 0.2 in the
univariate model were further analyzed in a multivariate model.
We report adjusted HRs from multivariate models as well as
the 95% confidence interval (CI) for each risk factor. p < 0.05
was considered statistically significant.
Results
Overall, 1598 patients with ICD-9-CM: 365.23, chronic angle
closure glaucoma visited our department in 2008. Among them,
eighty-nine eyes of 89 patients conformed to all the inclusion
and exclusion criteria. All of the patients were of Chinese
ethnicity, with a mean age of 69.8 ± 7.9 years at enrollment.
Six eyes (7%) had a history of prior AAC. Eighty-seven (98%)
patients had received laser peripheral iridotomy (LPI), and 2
(2%) patients without LPI had undergone combination surgery
consisting of cataract extraction and trabeculectomy previously.
Seventy-seven eyes (87%) were phakic at baseline. The
average MD of the first VF was -8.1 ± 4.4 dB and the mean
PSD was 6.9 ± 4.0 dB. The mean IOP during the study period
was 14.4 ± 2.3 mm Hg. The mean number of VF tests collected
was 6.9 ± 2.3 over a mean follow-up time of 63.9 ± 23.9
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months, ranging from 24.4 to 134.0 months, with 84 (94%)
patients followed up for more than 3 years.
During the follow-up period, 9 (10%) patients developed VF
progression. Demographic and clinical characteristics of these
2 groups are shown in Table 1. There was no statistical
difference between the 2 groups for any parameter (Table 1).
Only 4 patients had ACD and AL obtained with IOL Master, and
all of these patients were in the non-progression group.
Cox proportional hazards univariate analysis tested all of the
potentially relevant variables listed in Table 1. Only CCT and
AL were associated with VF progression at p < 0.2. The
univariate HR of CCT was 0.98 per μm thicker, 95% CI, 0.96 to
100 (p = 0.111). The univariate HR of AL was 0.35 per mm
longer, 95% CI, 0.13 to 0.91 (p = 0.031). Neither mean IOP nor
peak IOP was a risk factor for VF progression (p = 0.914 and
0.988, respectively). Likewise, neither IOP fluctuation nor IOP
range was relevant to VF progression (p = 0.566 and 0.561,
respectively). Given that age and gender are risk factors for
PAC, a multivariate analysis was performed with these 2
variables in addition to CCT and AL. It turned out that a longer
AL was a protective factor (adjusted HR, 0.28 per mm longer;
95% CI, 0.09 to 0.84; p = 0.023) (Table 2). If we excluded AL
data obtained with IOL Master, the AL variable still remained
significant (adjusted HR, 0.24 per mm longer; 95% CI, 0.07 to
0.78; p = 0.017).
Four of the nine patients with VF progression underwent
cataract surgery during the study period; they received cataract
surgery at least 1 year before VF progression was identified.
The mean interval between cataract operation and progression
was 30.0 ± 12.1 months, ranging from 12.3 to 43.5 months. In
the other five phakic eyes with VF progression, there was a
mean drop of 1.4 lines of BCVA at progression compared to
that at baseline (range, -3 to +2 lines; final BCVA range, 0.5 to
1.0).
Discussion
This study showed that a shorter AL was a risk factor for
progressive VF defects in Chinese patients under treatment for
PACG. To the best of our knowledge, this finding has never
been previously reported. To date, a standard criterion to
define VF progression is still lacking. However, the concensus
is to use event-based methods in the first few years of follow-
up when multiple VF tests are not available for an authentic
trend analysis. We adopted the CIGTS criteria to define VF
progression because it has been shown to have good
specificity and the best sustainablity as compared to other VF
progression algorithms [18].
Quek et al have reported that higher mean IOP and the
presence of previous AAC were associated with progression of
VF defects in a study of Chinese patients with PACG [15].
However, neither of these factors was identified as risk factors
for VF progression in our study. The discrepancy in study
results may be due to differences in the definition of VF
progression; AGIS system was used in Quek et al’s report and
CIGTS system in our study. Another possible explanation is
that the number of eyes (7%) with previous AAC was small in
our study compared with that (35%) in the study by Quek et al
[15]. In fact, if subjects with prior AAC were excluded, they
found mean IOP and the range of IOP were no longer
associated with VF progression. Quek et al reasoned that
mean IOP probably was higher in eyes with prior AAC due to
the acute pressure spikes and the difficulty in defining the end
of acute episodes [19].
The finding that a shorter AL was associated with disease
progression in treated PACG may be explained by a greater
circadian change in habitual IOP in those eyes with a shorter
Table 1. Comparison of clinical characteristics between




progression (n = 9)
No visual field
progression (n = 80) p value
Age, year 71.5 ± 6.5 69.6 ± 8.0 0.481a
Female sex, % 2 (22) 33 (41) 0.262b
Follow-up, month 65.8 ± 33.0 63.7 ± 23.0 0.809a
Diabetes mellitus, % 2 (22) 11 (14) 0.474b
Hypertension, % 5 (56) 35 (44) 0.505b
Smoker, % 0 (0) 6 (8) 0.401b
Positive family history of
glaucoma, %
0 (0) 4 (5) 0.498b
Previous acute angle
closure, %
1 (11) 5 (6) 0.685b
Phakic eyes at baseline, % 9 (100) 68 (85) 0.218b
Baseline IOP, mm Hg 16.2 ± 2.9 15.8 ± 3.7 0.732a
Baseline VF    
pattern standard deviation,
dB
7.1 ± 4.6 6.8 ± 4.0 0.834a
mean deviation, dB -7.8 ± 4.7 -8.2 ± 4.4 0.795a
Central corneal thickness,
μm
530.7 ± 39.2 548.4 ± 35.0 0.159a
Anterior chamber depth,
mm
2.5 ± 0.3 (n = 8) 2.5 ± 0.3 (n = 59) 0.923a
Lens thickness, mm 4.9 ± 0.5 (n = 8) 4.8 ± 0.6 (n = 54) 0.685a
Axial length, mm 22.5 ± 0.6 (n = 8) 23.1 ± 0.9 (n = 68) 0.074a
No. of VF examinations 6.8 ± 2.0 6.9 ± 2.4 0.846a
IOP, mm Hg 14.8 ± 2.4 14.3 ± 2.3 0.605a
IOP fluctuation, mm Hg 2.8 ± 0.9 2.2 ± 0.9 0.123a
IOP range, mm Hg 9.3 ± 2.3 10.8 ± 2.3 0.090a
Peak IOP, mm Hg 21.7 ± 5.4 20.2 ± 5.3 0.415a
Disc hemorrhage during
study period, %
1 (11) 6 (8) 0.685b
Surgery during study
periods
   
Trabeculectomy, % 1 (11) 8 (10) 0.474b
Cataract surgery, % 3 (33) 18 (23) 0.267b
Cataract and
trabeculectomy, %




Gonioplasty, % 0 (0) 2 (3)  
ALTP, % 0 (0) 6 (8)  
ALTP, argon laser trabeculoplasty; IOP, intraocular pressure; VF, visual field
a Independent samples t test; b Pearson Chi-Square
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AL. Loewen et al reported that a shorter AL was significantly
associated with greater posture-dependent changes in IOP
[20]. Other studies also found choroidal thickness was thicker
in eyes with a shorter AL and the increase in choroidal
thickness after water drinking was greater in eyes with angle
closure than in eyes with open angle [21,22]. Accordingly, it is
likely that eyes with a shorter AL are prone to greater
fluctuations of circadian IOP related to variations in physiology,
posture, and environmental stimulation, which contribute to
further damage of the optic nerve. In fact, in a study with a
mean follow-up of 9 years, higher IOP fluctuation was
associated with faster VF progression in PACG patients whose
IOP was maintained below 18 mm Hg after trabeculectomy and
phacoemulsification [14]. In our study, the mean IOP fluctuation
was higher in patients with VF progression than in those
without progression, albeit not reaching statistical significance.
It is worth noting that the so-called IOP fluctuations in almost all
clinical studies may not reflect the genuine circadian
fluctuations of pressure that act on the optic nerve head and
retinal nerve fiber. Despite the introduction of devices allegedly
being able to measure IOP in a continuous way without
interrupting sleep at night, the accuracy and feasibility of them
remain to be verified [23].
ACD was not associated with VF progression in both Quek et
al’s report [15] and the present study. These results
substantiate that central ACD is not a crucial parameter for
Chinese patients with PACG [24,25]. Nolan et al and Wang et
al have suggested that angle closure in Chinese was mainly
attributable to crowding of peripheral anterior chamber, plateau
iris configuration, or a combination of these features together
with pupil block, rather than pure pupil block [25,26].
Because of the strict criteria for inclusion and exclusion, only
89 eyes constituted this study and nine of them showed
progression. In addition to the small sample size, the limitations
of our study are related to the inherent bias of its retrospective
nature. Data of post-iridotomy gonioscopic finding is
incomplete. The AL measurements of 4 patients were obtained
using IOL Master instead of A-scan biometry. AL
measurements using IOL Master was longer than that obtained
with ultrasound biometry [27]. However, AL remained a
significant risk factor in multivariate analysis even when we
excluded these 4 patients. This study did not exclude patients
with coexistent cataract, so VF deterioration might be caused
by increasing severity of lens opacity. However, the BCVA
decreased slightly (< 2 lines) during the study period for the 5
eyes that remained phakic and showed VF progression.
Besides, VF progression was detected long after cataract
surgery for the 4 eyes that underwent cataract extraction during
the study period. This suggested that increasing lens opacity
was unlikely to be responsible for VF progression in our study.
This study demonstrates that a shorter AL is the only risk
factor for VF progression in PACG. With a larger sample size,
more risk factors associated with progression might be able to
be identified since small sample size creates a limitation in
performing multivariable analysis. Further prospective studies
using ultrasound biomicroscopy or anterior segment optical
coherence tomography are warranted to validate the biological
impact of AL on dynamic changes of the anterior chamber
angle and its possible role in PACG progression. Although IOP
was not identified as a risk factor, it must be noted that all
patients included in this study were treated by glaucoma
specialists with controlled IOP. Thus, the results of our study
are not applicable to PACG eyes with uncontrolled IOP.
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